Bharat Biotech’s COVID-19 vaccine has shown an overall interim clinical efficacy of 78 per cent and 100 per cent efficacy against severe COVID-19 disease.
Announcing the interim results from Phase III trials of its COVID-19 vaccine Covaxin, Bharat Biotech said the second interim analysis is based on accruing more than 87 symptomatic cases of COVID-19.
“Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per cent against mild, moderate, and severe COVID-19 disease.
The efficacy against severe COVID-19 disease was 100 per cent, with an impact on reduction in hospitalisations. The efficacy against asymptotic COVID-19 infection was 70 per cent, suggesting decreased transmission in COVAXIN recipients,” the company said in a statement.